ReviewHematology/oncology clinics of North America2014
Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
Review in Hematology/oncology clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- [Chinese guidelines for the diagnosis and treatment of hereditary hemochromatosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Guideline
- Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers.Drugs in R&D · 2024Trial
- Intestine-Specific Ferroportin Ablation Rescues from Systemic Iron Overload in Mice.Nutrients · 2026Article
- RationalJournal of medicinal chemistry · 2024Article
- Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.Haematologica · 2023Article
- Macrophage ferroportin serves as a therapeutic target against bacteria-induced acute lung injury by promoting barrier restoration.iScience · 2022Article
- Does Hepcidin Tuning Have a Role among Emerging Treatments for Thalassemia?Journal of clinical medicine · 2022Review
- β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.Hematology. American Society of Hematology. Education Program · 2021Review
- Novel Therapeutic Advances in β-Thalassemia.Biology · 2021Review
- Replacing the suppressed hormone: toward a better treatment for iron overload in β-thalassemia major?Haematologica · 2020Article
- Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.American journal of hematology · 2020Article
- New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia.Haematologica · 2019Article
- A Short Peptide Inhibitor as an Activity-Based Probe for Matriptase-2.Pharmaceuticals (Basel, Switzerland) · 2018Article
- Hepcidin agonists as therapeutic tools.Blood · 2018Review
- 3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach.Pharmaceuticals (Basel, Switzerland) · 2016Article
- Pharmacological Targeting of the Hepcidin/Ferroportin Axis.Frontiers in pharmacology · 2016Review
- The Frequency of Adrenal Insufficiency in Adolescents and Young Adults with Thalassemia Major versus Thalassemia Intermedia in Iran.Mediterranean journal of hematology and infectious diseases · 2015Article
- The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.Current atherosclerosis reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In this article, the authors discuss new approaches to treating iron overload diseases using hepcidin mimetics or by modulating endogenous hepcidin expression. In particular, the authors discuss lipid nanoparticle encapsulated siRNA and antisense oligonucleotide-mediated inhibition of TMPRSS6, an upstream regulator of hepcidin, and treatment with transferrin or hepcidin mimetics, including the recently described minihepcidins. In each case, in animal models of β-thalassemia, not only do the interventions affect iron absorption but they also act as disease-modifying agents that ameliorate the ineffective erythropoiesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.